- Home
- NDLS vs INMB Comparison
NDLS vs INMB Comparison
Compare NDLS & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NDLS | INMB |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 57.9M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NDLS | INMB |
|---|---|---|
| Price | $16.40 | $2.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 64.7K | ★ 453.8K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $495,089,000.00 | $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.37 | ★ 257.14 |
| 52 Week Low | $0.47 | $1.09 |
| 52 Week High | $19.00 | $2.61 |
Technical Indicators
Market Signals| Indicator | NDLS | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 63.70 |
| Support Level | $10.71 | $1.37 |
| Resistance Level | $16.10 | $2.17 |
| Average True Range (ATR) | 1.40 | 0.12 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 56.69 | 78.63 |
Price Performance
Historical ComparisonAbout NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.